Bristol Myers Squibb (BMY) closed the most recent trading day at $49.33, moving -1.35% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 2.24%. Elsewhere, ...

Pomalyst accounted for sales of more than $3 billion in each of the last five years, including $3.55 billion in 2024, accounting for 7% of Bristol's overall revenue of $48 billion. Related ...

With a market cap of $102.7 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company ...

Since my latest update (late October 2024), BMY is up over 15% while the S&P 500 index (SPX ... when the BMY stock set a new high, Bristol-Myers Squibb has been under continued market pressure ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 37,216 calls trading, 3x expected, and implied vol increasing almost 3 points to 39.30%. Jan-26 25 calls and May-25 43 calls are the ...

As you can see from the chart above the percentage of shares that are sold short for Bristol-Myers Squibb has grown since its last report. This does not mean that the stock is going to fall in the ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $59.21, reflecting a +0.03% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

Bristol Myers Squibb stock (NYSE: BMY) has gained 7% this year, outperforming the S&P 500 which has declined 1%. BMS’s strong Q4 performance has helped drive its positive momentum. While markets ...